Pylarify radiopharmaceutical
Active Awarded Last action
- Contract number
- 36C25026N0359
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,972,709
Award facts
- Contract value 100% obligated
- $1,972,708.80 Current and potential, with all options
- Completion date 64% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Bedford, MA 01730, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $1.97M by the Department of Veterans Affairs' Veterans Integrated Service Network 10 on March 1, 2026, for the supply of PYLARIFY radiopharmaceutical products. The contract is designated as a total small business set-aside and carries a firm fixed-price structure with an ultimate completion date of February 28, 2027. Performance will occur at the contractor's facility in Bedford, Massachusetts. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract, which establishes the pricing and terms for ongoing radiopharmaceutical procurement across the VA system.
PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography scans for the detection and localization of prostate cancer, providing critical diagnostic capabilities for federal healthcare providers serving veterans. This award reflects the ongoing federal demand for specialized nuclear medicine products and represents a continuation of Progenics' substantial presence as a primary supplier of radiopharmaceuticals to the VA, which has awarded the company over 150 individual contracts across multiple Veterans Integrated Service Networks, the Defense Health Agency, and the National Institutes of Health.
Quick answers
Who was awarded contract 36C25026N0359?
36C25026N0359 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on March 1, 2026.
How much is contract 36C25026N0359 worth?
The government has obligated $1,972,709 on 36C25026N0359.
Is contract 36C25026N0359 an order under another contract?
Yes. 36C25026N0359 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25026N0359 competed?
The extent of competition for 36C25026N0359 was full and open competition. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award